Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Gretchen Kimmick

Professor

Duke University

United States

Research Interests

Explore related searches

Professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (10)

Sarah Kelleher

Associate Professor

Duke University

UNITED STATES

View details

Adam Brufsky

University of Pittsburgh Medical Center

UNITED STATES

View details

Asal Pilehvari

Assistant Professor

University of Virginia

UNITED STATES

View details

Kelly Hyland

Assistant Professor

Medical University of South Carolina

UNITED STATES

View details

Dawn L. Hershman

Columbia University Irving Medical Center

UNITED STATES

View details

Joseph Winger

Associate Professor

Duke University

UNITED STATES

View details

Jennifer Plichta

Duke University

UNITED STATES

View details

Gayle Ackerman DiLalla

Duke University

UNITED STATES

View details

Karen Kaiser

Research Associate Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Jeffrey Switchenko

Emory University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gretchen Kimmick

Research Interests

Explore related searches

Articles (20)

Racial and socioeconomic disparities in frailty burden among older women with metastatic breast cancer: A SEER-Medicare analysis.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0

Adjuvant chemotherapy for breast cancer: are all dose reductions inappropriate?

Characterizing Alcohol Use and Expectancies for Alcohol Analgesia Among Breast Cancer Survivors With Arthralgia.

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer

Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer.

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2

Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.

Social wellbeing in older breast cancer survivors taking adjuvant endocrine therapy: impacts of self-efficacy for symptom management and pain.

ASO Visual Abstract: Adjuvant Radiation Versus Endocrine Therapy After Lumpectomy for Early Stage Breast Cancer in Older Women—Analysis of Real-World Survival Outcomes

Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes

Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain

Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011–2022

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2− Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered

Abstract P2-10-05: Survival in Older Women Receiving Adjuvant Radiation Monotherapy vs. Endocrine Monotherapy Following Lumpectomy

Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol.

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.

Disparities in receipt of 1-<sup>st</sup> line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.

Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses.

Collaborators (10)

Sarah Kelleher

Adam Brufsky

Asal Pilehvari

Kelly Hyland

Dawn L. Hershman

Joseph Winger

Jennifer Plichta

Gayle Ackerman DiLalla

Karen Kaiser

Jeffrey Switchenko

Make your next move.